Statement attributable to:
Ryan D. Mire, MD, MACP
President, ACP
WASHINGTON March 2, 2023 – The ¹Ü¼ÒÆÅÐÄË®ÂÛ̳ (ACP) is extremely encouraged by yesterday’s announcement from Eli Lilly that they are going to be limiting the cost of their insulin for patients. Too often our patients struggle to afford the medications they need to live, including insulin. A medication can only be as effective as a patient’s ability to obtain it. Ensuring that those who need it can afford their insulin enough to take their medication as directed will help my patients lead healthier lives. ACP has long for the need to address escalating prescription drug prices and is thankful to the Biden administration and Congress for starting an important discussion about the cost of this critical medication. We call on other manufacturers to follow suit and for Congress to cap insulin cost for patients with commercial insurance similar to the legislation they passed for the Medicare population.
***
About the ¹Ü¼ÒÆÅÐÄË®ÂÛ̳
The ¹Ü¼ÒÆÅÐÄË®ÂÛ̳ is the largest medical specialty organization in the United States with members in more than 145 countries worldwide. ACP membership includes 160,000 internal medicine physicians, related subspecialists, and medical students. Internal medicine physicians are specialists who apply scientific knowledge and clinical expertise to the diagnosis, treatment, and compassionate care of adults across the spectrum from health to complex illness. Follow ACP on , , and .
Contact: Jacquelyn Blaser, (202) 261-4572, jblaser@acponline.org